Richard Lowenthal

It's not a concern, but the effort of the agency on direct-to-consumer.

NEFI is actually kind of a poster child of a drug you want to advertise directly to consumers.

There's an underutilization of epinephrine.

Only about 15% of the patients that really should

have epinephrine, have it.

And on top of that, very, very few of them carry it and use it.

So there's a lot of lack of education and a lack of understanding in this market especially.

And by advertising directly to the consumers and getting them to even go to a website and check out research,

Well, what options do I have?

I didn't know there was an option other than injection, and I didn't want to get an injection because I won't inject myself.

Just people like that who we know 50% of the auto-injector prescriptions are refused, are not filled because people don't want them.

So it's not really a cost issue as much as people just don't want to get an injection.

The doctors prescribe it anyway for liability reasons.

but the people refuse to fill them.

So there's a huge benefit actually of informing them, educating them about different options and about the need for epinephrine in general.

And it's also why we're in partnership with Food Allergy Research and Education, also called FAIR.

They're the largest advocacy group in the world for food allergy and venom allergies.

And we're in a partnership with them.

We provide a sponsorship to them.

They're running public service announcements and we're, we're supporting that because it's not just about nephew.